Variants I1264M and V1347M Significantly Associated with Clinical Outcomes of Pediatric Neuroblastoma Patients Imply a New Prognostic Biomarker: A 121-Patient Cancer Genome Study.

Background: Neuroblastoma (N.B.) is the most common tumor in children. The gene (B Double Prime 1) plays a role in cancers but is less known in N.B. Thus, we conducted this study to investigate the value of mutations in N.B.

Methods: A dataset of 121 NB patients from the Cancer Genome Atlas database was used to analyze gene mutations by RNA sequencing. Kaplan-Meier estimates were performed for overall survival (O.S.) analysis on variants, and Cox's proportional hazards regression model was used for multivariate analysis.

Results: In 121 NB patients, we identified two variants of associated with N.B., located at chr5:71511131 and chr5:71510884. The prevalence of these variants, I1264M and V1347M, was 52.9% (64/121) and 45.5% (55/121), respectively. O.S. analysis showed a significant difference between subgroups with or without variants ( < 0.05). Multivariate analysis further revealed that ariants were independent prognostic variables in N.B. ( < 0.05).

Conclusion: Our results suggest variants are associated with significantly improved clinical outcomes in N.B., thus providing clinicians with a new tool.